Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies.

Abstract

Interim results of two open-label extension studies assessed ezogabine/retigabine safety and tolerability for partial-onset seizures. At data cutoff, 336 (60%) patients received ≥ 12 months' open-label ezogabine/retigabine. The most common TEAEs included dizziness (22%), somnolence (19%), headache (14%), and fatigue (10%). Change in seizure frequency from baseline (median reduction, 53%) and responder rate (52.5%) was maintained in patients remaining on ezogabine/retigabine. Continuous 6-month and 12-month seizure-free rates for ezogabine/retigabine exposures ≥ 12 months were 13.1% and 7.1%, respectively.

• Authors: Antonio Gil-Nagel, Martin J Brodie, Robert Leroy, Tracy Cyr, Susan Hall, Mary Castiglia, Colleen Twomey, Kevan VanLandingham
• Journal: Epilepsy research (Epilepsy Res) Vol. 102 Issue 1-2 Pg. 117-21 (Nov 2012) ISSN: 1872-6844 [Electronic] Netherlands
• PMID: 22771137 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2012. Published by Elsevier B.V.

Chemical References

• Anticonvulsants
• Carbamates
• Phenylenediamines
• ezogabine

Topics

• Adult
• Anticonvulsants (administration & dosage, adverse effects)
• Carbamates (administration & dosage, adverse effects)
• Dizziness (chemically induced)
• Drug Resistance
• Epilepsies, Partial (drug therapy)
• Fatigue (chemically induced)
• Female
• Headache (chemically induced)
• Humans
• Male
• Middle Aged
• Phenylenediamines (administration & dosage, adverse effects)
• Sleep Stages
• Time
• Treatment Outcome
• Young Adult